Spectrum Pharmaceuticals
11500 S. Eastern Ave
Henderson
NV
89052
United States
Tel: 1-702-835-6310
Website: https://www.sppirx.com/
74 articles with Spectrum Pharmaceuticals
-
Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
1/31/2023
Spectrum Pharmaceuticals, Inc. today announced business highlights and preliminary ROLVEDON net sales for the quarter and year ended December 31, 2022.
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff
1/26/2023
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on January 26, 2023, Spectrum’s Board of Directors granted an aggregate of 20,833 inducement restricted stock units (“RSUs”) to a commercial non-executive employees.
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff - December 27, 2022
12/27/2022
Spectrum Pharmaceuticals announced that on December 27, 2022, Spectrum’s Board of Directors granted an aggregate of 206,059 inducement restricted stock units to commercial non-executive employees who were hired specifically for the launch of ROLVEDON.
-
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
12/6/2022
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors.
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff - December 05, 2022
12/5/2022
Spectrum Pharmaceuticals announced that on December 5, 2022, Spectrum’s Board of Directors granted an aggregate of 736,988 inducement restricted stock units to commercial non-executive employees who were hired specifically for the launch of ROLVEDON.
-
Spectrum Pharmaceuticals made the call Friday to slash three-fourths of its workforce on the heels of a Complete Response Letter from the FDA.
-
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
11/25/2022
Spectrum Pharmaceuticals, Inc. today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Spectrum’s New Drug Application (NDA) for poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations.
-
The FDA has a number of PDUFA dates for the remainder of November for Spectrum, ImmunoGen, Scynexis and Y-mAbs.
-
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/10/2022
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period ended September 30, 2022.
-
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
10/21/2022
Spectrum Pharmaceuticals, Inc. today announced the commercial availability of ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
-
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
9/23/2022
Spectrum Pharmaceuticals, Inc. today announced that it has entered into a five-year debt financing agreement with investment affiliates managed by SLR Capital Partners, LLC (SLR) for a term loan facility of up to $65 million.
-
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
-
Shares of Spectrum Pharmaceuticals plunged 33% upon the release of briefing documents for an FDA advisory meeting regarding poziotinib
-
Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting
9/22/2022
Spectrum Pharmaceuticals (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration’s (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”) met to review poziotinib for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (“NSCLC”) harboring HER2 exon 20 insertion mutations.
-
The FDA has two PDUFA dates on its calendar this week, with two extra days slotted for an advisory committee meeting to evaluate drug applications from three companies.
-
Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
9/10/2022
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced data from a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer.
-
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
9/9/2022
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved ROLVEDON™.
-
Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
9/5/2022
Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced a poster presentation titled: High Activity of Poziotinib in G778_P780dup HER2 Exon 20 Insertion Mutations in Non-Small Lung Cancer.
-
Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/11/2022
Spectrum Pharmaceuticals, Inc. announced today financial results for the three-month period ended June 30, 2022 and provided a corporate update.
-
Spectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update
7/29/2022
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific.